Omnicell (OMCL) Misses Q4 EPS by 1c, Revenues Beat; Offers FY20 EPS Mid-Point Guidance Above Consensus, FY20 Revenue Views Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Omnicell (OMCL) Misses Q4 EPS by 1c, Revenues Beat; Offers FY20 EPS Mid-Point Guidance Above Consensus, FY20 Revenue Views Above Consensus

Omnicell Reports Fiscal Year and Fourth Quarter 2019 Results

February 6, 2020 4:01 PM EST

Record annual GAAP and non-GAAP revenues of $897.0 million

Record 2019 GAAP net income per diluted share of $1.43

Record 2019 non-GAAP net income per diluted share of $2.81

Record ending product backlog of $588 million

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its fiscal year and fourth quarter ended December 31, 2019.

This press release features multimedia. View... More